By: IPP Bureau
Last updated : August 01, 2026 1:04 am
The company's EBITDA rose 38.6% year-on-year to Rs. 804.8 crore, while EBITDA margin improved to 20.03%
Glenmark Pharmaceuticals Ltd. reported a strong start to FY27, with consolidated revenue increasing 23.1% year-on-year to Rs. 4,018.5 crore for the quarter ended June 30, 2026, compared to Rs. 3,264.4 crore in the corresponding period last year.
The company's EBITDA rose 38.6% year-on-year to Rs. 804.8 crore, while EBITDA margin improved to 20.03%. Profit after tax (PAT) stood at Rs. 482.8 crore during the quarter, translating into a PAT margin of 11.8%.
The performance was supported by broad-based growth across Glenmark's key markets, including India, North America and Emerging Markets.
Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said the company had begun FY27 on a strong note with robust execution across its global operations. He highlighted that the India business continued to outperform the market, while North America posted healthy underlying growth driven by first-to-market respiratory product launches. Emerging Markets also maintained strong momentum.
Saldanha said the company remains focused on strengthening its core businesses while expanding its specialty and innovation-led portfolio.
He noted that the global growth of RYALTRIS, increasing traction for WINLEVI across Europe, and continued progress in Glenmark's oncology portfolio and the pipeline of its innovation arm, IGI, position the company for sustainable and profitable long-term growth.